Du Lingbin, Zhao Zixuan, Zheng Rongshou, Li Huizhang, Zhang Siwei, Li Runhua, Wei Wenqiang, He Jie
Department of Cancer Prevention, Institute of Cancer and Basic Medicine, Zhejiang Cancer Hospital, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China.
Center for Health Policy Studies, School of Medicine, Zhejiang University, Hangzhou, China.
Front Oncol. 2020 Nov 10;10:1702. doi: 10.3389/fonc.2020.01702. eCollection 2020.
Using data from cancer registries to estimate thyroid cancer incidence and mortality in China, 2015. Data submitted from local cancer registries were checked and evaluated according to the criteria of data quality control, a total of 368 cancer registries' data were qualified for the final analysis. Data were stratified by area (urban/rural, eastern/central/western), sex and age, combined with national population data to estimate thyroid cancer incidence and mortality in China, 2015. Approximately 200,700 new cases were diagnosed in 2015, accounting for 5.11% of all cancer cases. The crude incidence rate was 14.60/100,000. Age-standardized incidence rates by Chinese standard population (ASIRC) and world standard population (ASIRW) were 12.05/100,000 and 10.44/100,000, with the cumulative incidence rate (0-74 years old) of 1.00%. About 7,900 deaths of thyroid cancer were reported in 2015, accounting for 0.34% of all cancer deaths. The crude mortality rate was 0.58/100,000, age-standardized mortality rates by Chinese standard population (ASMRC) and world standard population (ASMRW) were 0.37/100,000 and 0.36/100,000. The age-standardized incidence and mortality in females were significantly higher than those in males ( < 0.001). The rates in urban areas were higher than those in rural areas ( < 0.001). The ASIRC in eastern areas was higher than that in central and western areas ( < 0.001), while the ASMRC in central areas was higher than that in eastern and western areas ( < 0.001). The burden of thyroid cancer was heavy in China, cancer control faces the problem of the disparity between geographic areas, and the incidence and mortality rates were varied by sex and age. Targeted cancer preventive measures should be put into practice.
利用癌症登记处的数据估算2015年中国甲状腺癌的发病率和死亡率。根据数据质量控制标准对各地癌症登记处提交的数据进行检查和评估，共有368个癌症登记处的数据符合最终分析要求。数据按地区（城市/农村、东部/中部/西部）、性别和年龄进行分层，并结合全国人口数据来估算2015年中国甲状腺癌的发病率和死亡率。2015年约有200700例新发病例被诊断出来，占所有癌症病例的5.11%。粗发病率为14.60/10万。按中国标准人口计算的年龄标准化发病率（ASIRC）和按世界标准人口计算的年龄标准化发病率（ASIRW）分别为12.05/10万和10.44/10万，累积发病率（0至74岁）为1.00%。2015年报告了约7900例甲状腺癌死亡病例，占所有癌症死亡病例的0.34%。粗死亡率为0.58/10万，按中国标准人口计算的年龄标准化死亡率（ASMRC）和按世界标准人口计算的年龄标准化死亡率（ASMRW）分别为0.37/10万和0.36/10万。女性的年龄标准化发病率和死亡率显著高于男性（<0.001）。城市地区的发病率高于农村地区（<0.001）。东部地区的ASIRC高于中部和西部地区（<0.001），而中部地区的ASMRC高于东部和西部地区（<0.001）。中国甲状腺癌负担沉重，癌症防控面临地区差异问题，发病率和死亡率因性别和年龄而异。应实施有针对性的癌症预防措施。
